A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 2)
Raymond and Alex in 2022. Photo courtesy of Alex Gaudlap

A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 2)

Before you read on, don't forget to check out Part 1 of our interview. In Part 1, Alex discusses the multi-year diagnostic odyssey to discover that Raymond has VAMP2. Today, we talk…

Continue Reading A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 2)
A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 1)
Raymond and Alex in 2022. Photo courtesy of Alex Gaudlap

A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 1)

In the United States, rare diseases are defined as those affecting fewer than 200,000 people. In the cases of ultra-rare conditions, there is often even less research, less resources, and…

Continue Reading A Ray of Sunshine: Alex Gaudlap’s Efforts to Raise Awareness of the Ultra-Rare VAMP2 (Pt. 1)
Finding Balance with CDKL5 Deficiency Disorder: Whitney and Havilah’s Story (Pt. 1)
Photo courtesy of Whitney Mitchell

Finding Balance with CDKL5 Deficiency Disorder: Whitney and Havilah’s Story (Pt. 1)

A year after her daughter Havilah was diagnosed with CDKL5 deficiency disorder (CDD), Whitney Mitchell’s pediatrician looked her in the eyes and said something that Whitney still carries with her…

Continue Reading Finding Balance with CDKL5 Deficiency Disorder: Whitney and Havilah’s Story (Pt. 1)

INTERVIEW: Albireo’s CEO Ron Cooper Talks Patient-Centricity, PFIC, and Study Updates

Each week, in an email to his team, Albireo Pharma CEO Ron Cooper sends out the story of a child or family affected by conditions such as PFIC or Alagille…

Continue Reading INTERVIEW: Albireo’s CEO Ron Cooper Talks Patient-Centricity, PFIC, and Study Updates
INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)
source: pixabay.com

INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)

Did you know that November is considered to be Hyperhidrosis Awareness Month? This awareness campaign is intended to share information about hyperhidrosis (a medical condition causing excessive and uncontrolled sweating),…

Continue Reading INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)
INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Courtesy of Omega

INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma

Mahesh Karande, the President and CEO of Omega Therapeutics, is incredibly passionate about epigenetics. And it shows: in the work that he and his team do, in the therapies they…

Continue Reading INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, we discussed Dr. Sumeray's background, what hypoparathyroidism is, and its symptoms and treatments. Today, we're…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)

When it comes to drug development and medical research, particularly within the rare disease sphere, it is incredibly important for patients to feel involved in the process. After all, patients…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)
INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, Chris Peetz discusses his background, why he joined Mirum, and the process of evaluating LIVMARLI…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 2)
INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)
Photo courtesy of Mirum

INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)

The American Association for the Study of Liver Disease (AASLD) held its annual Liver Meeting from November 4-7, 2022 in Washington, D.C. During the meeting, Mirum Pharmaceuticals shared two late-breaker…

Continue Reading INTERVIEW: Mirum’s Chris Peetz Discusses Positive Topline Data on LIVMARLI for PFIC (Pt. 1)
CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 2)
Photo courtesy of CureDuchenne

CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 2)

Before you read on, don't forget to check out Part 1 of our interview with Jennifer Wallace Valdes, PT. In Part 1, Jennifer discusses her background, what Duchenne muscular dystrophy (DMD) is,…

Continue Reading CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 2)
Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA
Photo courtesy of Sangamo

Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA

The European Society for Gene and Cell Therapy (ESGCT) recently held its Annual Congress from October 11-14, 2022. During the ESGCT Congress, various stakeholders discussed data, trends, and new research…

Continue Reading Evaluating ST-920 for Fabry Disease: An Interview with Sangamo’s Bettina Cockroft, MD, MBA
CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 1)
Photo courtesy of CureDuchenne

CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 1)

Occupational therapy for individuals with Duchenne muscular dystrophy (DMD) requires a unique and specialized approach to maximize benefit and reduce harm. It is incredibly important that those performing occupational therapy…

Continue Reading CureDuchenne Has Launched a Certified Occupational Therapist Program: An Interview with Jennifer Wallace Valdes, PT (Pt. 1)
Advancing Research into Chronic Granulomatous Disease (CGD): An Interview with Dr. Katz (Pt. 2)
Dr. Katz

Advancing Research into Chronic Granulomatous Disease (CGD): An Interview with Dr. Katz (Pt. 2)

Don't forget to read Part 1 of our interview. In Part 1, we discussed what chronic granulomatous disease (CGD) is, how it is treated, and how parents and physicians can identify an…

Continue Reading Advancing Research into Chronic Granulomatous Disease (CGD): An Interview with Dr. Katz (Pt. 2)